Skip to content

Biosimilars Review & Report

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Biosimilar Approval Status
Home
- Home
About BR&R
News and Commentary
BR&R Manufacturer Profiles
Contact Us

$0.00 0 items

Neulasta-onbody_injector-png

Stanton Mehr July 16, 2021

Published by Stanton Mehr

View all posts by Stanton Mehr

Published July 16, 2021

Post navigation

Previous Post Amgen Crosses Biosimilar Misinformation Line, Says FDA

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Search for:

Recent Posts

Sandoz’s Wide Biosimilar Pipeline Getting Much Wider September 9, 2026
Biosimilar Bytes: Alvotech Biosimilar News and 6-Month Ustekinumab Switching Outcomes September 3, 2026
The Bona Fide Marketing Standard and What That Means for Biosimilars and Generics August 20, 2026
US Humira Sales Overwhelmed by Biosimilar Competition August 17, 2026
The Second Entyvio Biosimilar Is Under Review at FDA August 12, 2026
340B Pilot Program Could Be Big Boon for Biosimilars August 11, 2026
MFP Agreements Don’t Guarantee Better Patient Access August 7, 2026

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Recent Comments

	Drug Manufacturers’… on The Inflation Reduction Act: R…
	Drug Manufacturers’… on Thirty Years of Exclusivity fo…
	Manjiri Kulkarni on What is Cordavis and Why Will…
	MK on Where’s Pfizer’s Adalimumab Bi…
	Vinay Patel on The Adalimumab Biosimilar Grea…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Top Posts & Pages

The Evolution of the Biosimilars Market
Sandoz’s Wide Biosimilar Pipeline Getting Much Wider
Biosimilar Approval Status
US Humira Sales Overwhelmed by Biosimilar Competition
Amgen Manufacturer Profile FINAL
Samsung Bioepis Manufacturer Profile June 2026 Update
Biosimilar Bytes: Alvotech Biosimilar News and 6-Month Ustekinumab Switching Outcomes
Update on Amgen’s Pavblu Launch Success
Are Biosimilar Patient Copay Assistance Programs Lacking?
The Second Entyvio Biosimilar Is Under Review at FDA

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.

To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

X
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions
Privacy Policy

Copyright

Copyright 2013-2026 by SM Health Communications LLC. All Rights Reserved

Powered by WordPress.com.